InsidersTradesSigma
IRLAB Therapeutics AB Stock: price and management transactions · Finland · FIN-FSA
Follow the IRLAB Therapeutics AB share price and the full insider trade history of the company, a publicly traded company based in Finland. Shares are listed on FI FI, under the supervision of FIN-FSA. Operating in the Health Care sector, IRLAB Therapeutics AB has recorded 17 public disclosures. Market capitalisation: €121m. The latest transaction was disclosed on 9 July 2026 (Purchase). Among the most active insiders: James Gamgort. Every trade is free.
17
Insider Decl.
0
Thresholds
€466,758
17 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate IRLAB Therapeutics AB Strong Buy (bullish), based on 1 analysts. Average price target: SEK 7.50.
38Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 9 July 2026
Declarations17 total
10,500 shares@ €0.14AktieFI:csv-7a3c2db5bd0c5cc0c6bf
Ideal exit: 4 Apr 2027 (T+270)
200,000 shares@ €0.15AktieFI:csv-4d1c5ffaada541c4ab44
Ideal exit: 3 Apr 2027 (T+270)
10,500 shares@ €0.140.014% mcap4.7% of flowAktieFI:csv-35717e7a0931ae76cb93
Ideal exit: 4 Apr 2027 (T+270)
200,000 shares@ €0.150.28% mcap100.0% of flowAktieFI:csv-844ff39e4cac1d0d42e2
Ideal exit: 3 Apr 2027 (T+270)
97,369 shares@ SEK 1.200.10% mcap32.5% of flowAktieFI:csv-75e3ad9e602aca825661
Ideal exit: 30 Mar 2027 (T+270)
202,631 shares@ SEK 1.200.22% mcap67.5% of flowBTA (betald tecknad aktie)FI:csv-22bfd22bba1034efbae4
Ideal exit: 30 Mar 2027 (T+270)
140,716 shares@ SEK 1.200.15% mcap67.5% of flowBTA (betald tecknad aktie)FI:csv-2c830c6519ddb45ef9a1
Ideal exit: 30 Mar 2027 (T+270)
67,618 shares@ SEK 1.200.071% mcap32.5% of flowAktieFI:csv-6afbe8f6601ec1188497
Ideal exit: 30 Mar 2027 (T+270)
112,573 shares@ SEK 1.200.12% mcap67.5% of flowBTA (betald tecknad aktie)FI:csv-a2fc0dc8407569dc4fe0
Ideal exit: 30 Mar 2027 (T+270)
54,094 shares@ SEK 1.200.057% mcap32.5% of flowAktieFI:csv-38d280ab09db282c0366
Ideal exit: 30 Mar 2027 (T+270)
66,142 shares@ SEK 1.200.0068% mcap100.0% of flowBTA (betald tecknad aktie)FI:csv-7f4c847a7582f9e90c96
Ideal exit: 23 Mar 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
427,416 shares@ SEK 1.200.044% mcap100.0% of flowBTA (betald tecknad aktie)FI:csv-bc0ef732bc436e9724fa
Ideal exit: 23 Mar 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
555,842 shares@ SEK 1.200.057% mcap22.5% of flowBTA (betald tecknad aktie)FI:csv-442236d17577c19fb895
Ideal exit: 23 Mar 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
555,842 shares@ SEK 1.200.057% mcap22.5% of flowBTA (betald tecknad aktie)FI:csv-042e9dab302a546e5d34
Ideal exit: 23 Mar 2027 (T+270)
36,000 shares@ €0.31230.010% mcap100.0% of flowBTA (betald tecknad aktie)FI:A003R127-1
Ideal exit: 21 Apr 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
357,327 shares@ €0.30960.10% mcap75.5% of flowBTA (betald tecknad aktie)FI:A003Q791-1
Ideal exit: 14 Apr 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
116,196 shares@ €0.30960.033% mcap24.5% of flowBTA (betald tecknad aktie)FI:A003Q787-1
Ideal exit: 13 Apr 2026 (T+270)
17 of 17 declarations
About IRLAB Therapeutics AB
IRLAB Therapeutics AB is a Swedish biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It is listed on the Stockholm Stock Exchange (XSTO).